{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T23:45:08Z","timestamp":1792453508945,"version":"4.5.0"},"reference-count":165,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2018,4,30]],"date-time":"2018-04-30T00:00:00Z","timestamp":1525046400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Gastroenterol Hepatol"],"published-print":{"date-parts":[[2018,7]]},"DOI":"10.1038\/s41575-018-0010-0","type":"journal-article","created":{"date-parts":[[2018,4,30]],"date-time":"2018-04-30T06:44:19Z","timestamp":1525070659000},"page":"425-439","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":265,"title":["Risk of cardiomyopathy and cardiac arrhythmias in patients with nonalcoholic fatty liver disease"],"prefix":"10.1038","volume":"15","author":[{"given":"Quentin M.","family":"Anstee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Mantovani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herbert","family":"Tilg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4325-3900","authenticated-orcid":false,"given":"Giovanni","family":"Targher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,4,30]]},"reference":[{"key":"10_CR1","first-page":"1388","volume":"64","author":"European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD) & European Association for the Study of Obesity (EASO)","year":"2016","unstructured":"European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD) & European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J. Hepatol. 64, 1388\u20131402 (2016).","journal-title":"J. Hepatol."},{"key":"10_CR2","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1016\/j.dld.2015.08.004","volume":"47","author":"A Lonardo","year":"2015","unstructured":"Lonardo, A. et al. Epidemiological modifiers of non-alcoholic fatty liver disease: focus on high-risk groups. Dig. Liver Dis. 47, 997\u20131006 (2015).","journal-title":"Dig. Liver Dis."},{"key":"10_CR3","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1002\/hep.28431","volume":"64","author":"ZM Younossi","year":"2016","unstructured":"Younossi, Z. M. et al. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 64, 73\u201384 (2016).","journal-title":"Hepatology"},{"key":"10_CR4","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1038\/nrgastro.2016.147","volume":"14","author":"H Tilg","year":"2017","unstructured":"Tilg, H., Moschen, A. R. & Roden, M. NAFLD and diabetes mellitus. Nat. Rev. Gastroenterol. Hepatol. 14, 32\u201342 (2017).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10_CR5","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1056\/NEJMra0912063","volume":"363","author":"G Targher","year":"2010","unstructured":"Targher, G., Day, C. P. & Bonora, E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N. Engl. J. Med. 363, 1341\u20131350 (2010).","journal-title":"N. Engl. J. Med."},{"key":"10_CR6","doi-asserted-by":"publisher","first-page":"S47","DOI":"10.1016\/j.jhep.2014.12.012","volume":"62","author":"CD Byrne","year":"2015","unstructured":"Byrne, C. D. & Targher, G. NAFLD: a multisystem disease. J. Hepatol. 62, S47\u201364 (2015).","journal-title":"J. Hepatol."},{"key":"10_CR7","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1136\/gutjnl-2017-313884","volume":"66","author":"LA Adams","year":"2017","unstructured":"Adams, L. A., Anstee, Q. M., Tilg, H. & Targher, G. Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases. Gut 66, 1138\u20131153 (2017).","journal-title":"Gut"},{"key":"10_CR8","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1002\/hep.28785","volume":"64","author":"ZM Younossi","year":"2016","unstructured":"Younossi, Z. M. et al. The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe. Hepatology 64, 1577\u20131586 (2016).","journal-title":"Hepatology"},{"key":"10_CR9","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1002\/hep.21983","volume":"47","author":"G Perseghin","year":"2008","unstructured":"Perseghin, G. et al. Increased mediastinal fat and impaired left ventricular energy metabolism in young men with newly found fatty liver. Hepatology 47, 51\u201358 (2008).","journal-title":"Hepatology"},{"key":"10_CR10","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.jacc.2010.02.049","volume":"56","author":"LJ Rijzewijk","year":"2010","unstructured":"Rijzewijk, L. J. et al. Effects of hepatic triglyceride content on myocardial metabolism in type 2 diabetes. J. Am. Coll. Cardiol. 56, 225\u2013233 (2010).","journal-title":"J. Am. Coll. Cardiol."},{"key":"10_CR11","doi-asserted-by":"publisher","first-page":"E282","DOI":"10.1152\/ajpendo.00604.2005","volume":"291","author":"R Lautamaki","year":"2006","unstructured":"Lautamaki, R. et al. Liver steatosis coexists with myocardial insulin resistance and coronary dysfunction in patients with type 2 diabetes. Am. J. Physiol. Endocrinol. Metab. 291, E282\u2013E290 (2006).","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"10_CR12","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1097\/01.mcg.0000225668.53673.e6","volume":"40","author":"S Goland","year":"2006","unstructured":"Goland, S. et al. Cardiac abnormalities as a new manifestation of nonalcoholic fatty liver disease: echocardiographic and tissue Doppler imaging assessment. J. Clin. Gastroenterol. 40, 949\u2013955 (2006).","journal-title":"J. Clin. Gastroenterol."},{"key":"10_CR13","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.numecd.2008.12.007","volume":"19","author":"F Fallo","year":"2009","unstructured":"Fallo, F. et al. Non-alcoholic fatty liver disease is associated with left ventricular diastolic dysfunction in essential hypertension. Nutr. Metab. Cardiovasc. Dis. 19, 646\u2013653 (2009).","journal-title":"Nutr. Metab. Cardiovasc. Dis."},{"key":"10_CR14","first-page":"457","volume":"17","author":"H Fotbolcu","year":"2010","unstructured":"Fotbolcu, H. et al. Impairment of the left ventricular systolic and diastolic function in patients with non-alcoholic fatty liver disease. Cardiol. J. 17, 457\u2013463 (2010).","journal-title":"Cardiol. J."},{"key":"10_CR15","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1007\/BF03345421","volume":"35","author":"A Mantovani","year":"2012","unstructured":"Mantovani, A., Zoppini, G., Targher, G., Golia, G. & Bonora, E. Non-alcoholic fatty liver disease is independently associated with left ventricular hypertrophy in hypertensive Type 2 diabetic individuals. J. Endocrinol. Invest. 35, 215\u2013218 (2012).","journal-title":"J. Endocrinol. Invest."},{"key":"10_CR16","doi-asserted-by":"publisher","first-page":"389","DOI":"10.2337\/dc11-1820","volume":"35","author":"S Bonapace","year":"2012","unstructured":"Bonapace, S. et al. Nonalcoholic fatty liver disease is associated with left ventricular diastolic dysfunction in patients with type 2 diabetes. Diabetes Care 35, 389\u2013395 (2012).","journal-title":"Diabetes Care"},{"key":"10_CR17","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/j.jhep.2012.11.015","volume":"58","author":"K Hallsworth","year":"2013","unstructured":"Hallsworth, K. et al. Cardiac structure and function are altered in adults with non-alcoholic fatty liver disease. J. Hepatol. 58, 757\u2013762 (2013).","journal-title":"J. Hepatol."},{"key":"10_CR18","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1136\/heartjnl-2013-305099","volume":"100","author":"NH Kim","year":"2014","unstructured":"Kim, N. H. et al. Non-alcoholic fatty liver disease, metabolic syndrome and subclinical cardiovascular changes in the general population. Heart 100, 938\u2013943 (2014).","journal-title":"Heart"},{"key":"10_CR19","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1097\/MEG.0000000000000008","volume":"26","author":"CY Karabay","year":"2014","unstructured":"Karabay, C. Y. et al. Impaired left ventricular mechanics in nonalcoholic fatty liver disease: a speckle-tracking echocardiography study. Eur. J. Gastroenterol. Hepatol. 26, 325\u2013331 (2014).","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"10_CR20","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1002\/hep.27869","volume":"62","author":"LB VanWagner","year":"2015","unstructured":"VanWagner, L. B. et al. Association of nonalcoholic fatty liver disease with subclinical myocardial remodeling and dysfunction: a population-based study. Hepatology 62, 773\u2013783 (2015).","journal-title":"Hepatology"},{"key":"10_CR21","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s12933-015-0187-2","volume":"14","author":"S Cassidy","year":"2015","unstructured":"Cassidy, S. et al. Cardiac structure and function are altered in type 2 diabetes and non-alcoholic fatty liver disease and associate with glycemic control. Cardiovasc. Diabetol. 14, 23 (2015).","journal-title":"Cardiovasc. Diabetol."},{"key":"10_CR22","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1042\/CS20130298","volume":"126","author":"G Kocabay","year":"2014","unstructured":"Kocabay, G. et al. Left atrial deformation parameters in patients with non-alcoholic fatty liver disease: a 2D speckle tracking imaging study. Clin. Sci. 126, 297\u2013304 (2014).","journal-title":"Clin. Sci."},{"key":"10_CR23","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCIMAGING.114.001979","volume":"8","author":"M Graner","year":"2015","unstructured":"Graner, M. et al. Ectopic fat depots and left ventricular function in nondiabetic men with nonalcoholic fatty liver disease. Circ. Cardiovasc. Imag. 8, e001979 (2015).","journal-title":"Circ. Cardiovasc. Imag."},{"key":"10_CR24","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0135329","volume":"10","author":"A Mantovani","year":"2015","unstructured":"Mantovani, A. et al. Nonalcoholic fatty liver disease is independently associated with early left ventricular diastolic dysfunction in patients with type 2 diabetes. PLoS ONE 10, e0135329 (2015).","journal-title":"PLoS ONE"},{"key":"10_CR25","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1016\/j.jhep.2014.11.030","volume":"62","author":"S Petta","year":"2015","unstructured":"Petta, S. et al. Epicardial fat, cardiac geometry and cardiac function in patients with non-alcoholic fatty liver disease: association with the severity of liver disease. J. Hepatol. 62, 928\u2013933 (2015).","journal-title":"J. Hepatol."},{"key":"10_CR26","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1111\/1755-5922.12145","volume":"33","author":"M Sunbul","year":"2015","unstructured":"Sunbul, M. et al. Nonalcoholic steatohepatitis score is an independent predictor of right ventricular dysfunction in patients with nonalcoholic fatty liver disease. Cardiovasc. Ther. 33, 294\u2013299 (2015).","journal-title":"Cardiovasc. Ther."},{"key":"10_CR27","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1177\/0003319715576672","volume":"67","author":"SN Psychari","year":"2016","unstructured":"Psychari, S. N. et al. Epicardial fat in nonalcoholic fatty liver disease: properties and relationships with metabolic factors, cardiac structure, and cardiac function. Angiology 67, 41\u201348 (2016).","journal-title":"Angiology"},{"key":"10_CR28","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1177\/0161734615595015","volume":"38","author":"O Ozveren","year":"2016","unstructured":"Ozveren, O. et al. Doppler tissue evaluation of atrial conduction properties in patients with non-alcoholic fatty-liver disease. Ultrason. Imag. 38, 225\u2013235 (2016).","journal-title":"Ultrason. Imag."},{"key":"10_CR29","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1148\/radiol.2015150035","volume":"279","author":"RL Widya","year":"2016","unstructured":"Widya, R. L. et al. Association between hepatic triglyceride content and left ventricular diastolic function in a population-based cohort: the Netherlands epidemiology of obesity study. Radiology 279, 443\u2013450 (2016).","journal-title":"Radiology"},{"key":"10_CR30","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.ijcard.2016.06.180","volume":"221","author":"FM Trovato","year":"2016","unstructured":"Trovato, F. M. et al. Echocardiography and NAFLD (non-alcoholic fatty liver disease). Int. J. Cardiol. 221, 275\u2013279 (2016).","journal-title":"Int. J. Cardiol."},{"key":"10_CR31","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1111\/hepr.12770","volume":"47","author":"JY Jung","year":"2017","unstructured":"Jung, J. Y. et al. Effect of non-alcoholic fatty liver disease on left ventricular diastolic function and geometry in the Korean general population. Hepatol. Res. 47, 522\u2013532 (2017).","journal-title":"Hepatol. Res."},{"key":"10_CR32","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1002\/oby.21879","volume":"25","author":"TG Simon","year":"2017","unstructured":"Simon, T. G., Bamira, D. G., Chung, R. T., Weiner, R. B. & Corey, K. E. Nonalcoholic steatohepatitis is associated with cardiac remodeling and dysfunction. Obesity 25, 1313\u20131316 (2017).","journal-title":"Obesity"},{"key":"10_CR33","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1016\/j.jhep.2017.11.023","volume":"68","author":"YH Lee","year":"2018","unstructured":"Lee, Y. H. et al. Association of nonalcoholic steatohepatitis with subclinical myocardial dysfunction in non-cirrhotic patients. J. Hepatol. 68, 764\u2013772 (2018).","journal-title":"J. Hepatol."},{"key":"10_CR34","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1016\/j.amjcard.2013.03.056","volume":"112","author":"A Sert","year":"2013","unstructured":"Sert, A. et al. Left ventricular function by echocardiography, tissue Doppler imaging, and carotid intima-media thickness in obese adolescents with nonalcoholic fatty liver disease. Am. J. Cardiol. 112, 436\u2013443 (2013).","journal-title":"Am. J. Cardiol."},{"key":"10_CR35","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1016\/j.cjca.2012.07.846","volume":"29","author":"H Alp","year":"2013","unstructured":"Alp, H. et al. Association between nonalcoholic fatty liver disease and cardiovascular risk in obese children and adolescents. Can. J. Cardiol. 29, 1118\u20131125 (2013).","journal-title":"Can. J. Cardiol."},{"key":"10_CR36","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1016\/j.jpeds.2012.11.024","volume":"162","author":"GK Singh","year":"2013","unstructured":"Singh, G. K. et al. Alterations in ventricular structure and function in obese adolescents with nonalcoholic fatty liver disease. J. Pediatr. 162, 1160\u20131168.e1 (2013).","journal-title":"J. Pediatr."},{"key":"10_CR37","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1002\/hep.26610","volume":"59","author":"L Pacifico","year":"2014","unstructured":"Pacifico, L. et al. Left ventricular dysfunction in obese children and adolescents with nonalcoholic fatty liver disease. Hepatology 59, 461\u2013470 (2014).","journal-title":"Hepatology"},{"key":"10_CR38","doi-asserted-by":"publisher","first-page":"213737","DOI":"10.1155\/2015\/213737","volume":"2015","author":"E Bonci","year":"2015","unstructured":"Bonci, E. et al. Association of nonalcoholic fatty liver disease with subclinical cardiovascular changes: a systematic review and meta-analysis. Biomed. Res. Int. 2015, 213737 (2015).","journal-title":"Biomed. Res. Int."},{"key":"10_CR39","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1161\/ATVBAHA.110.207340","volume":"30","author":"R Dhingra","year":"2010","unstructured":"Dhingra, R. et al. Serum gamma-glutamyl transferase and risk of heart failure in the community. Arterioscler. Thromb. Vasc. Biol. 30, 1855\u20131860 (2010).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10_CR40","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1161\/ATVBAHA.111.240457","volume":"32","author":"SG Wannamethee","year":"2012","unstructured":"Wannamethee, S. G., Whincup, P. H., Shaper, A. G., Lennon, L. & Sattar, N. Gamma-glutamyltransferase, hepatic enzymes, and risk of incident heart failure in older men. Arterioscler. Thromb. Vasc. Biol. 32, 830\u2013835 (2012).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10_CR41","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1136\/heartjnl-2012-302972","volume":"99","author":"Y Wang","year":"2013","unstructured":"Wang, Y. et al. Serum gamma-glutamyltransferase and the risk of heart failure in men and women in Finland. Heart 99, 163\u2013167 (2013).","journal-title":"Heart"},{"key":"10_CR42","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000002760","volume":"95","author":"F Valbusa","year":"2016","unstructured":"Valbusa, F. et al. Nonalcoholic fatty liver disease is associated with higher 1-year all-cause rehospitalization rates in patients admitted for acute heart failure. Medicine 95, e2760 (2016).","journal-title":"Medicine"},{"key":"10_CR43","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0173398","volume":"12","author":"F Valbusa","year":"2017","unstructured":"Valbusa, F. et al. Nonalcoholic fatty liver disease and increased risk of 1-year all-cause and cardiac hospital readmissions in elderly patients admitted for acute heart failure. PLoS ONE 12, e0173398 (2017).","journal-title":"PLoS ONE"},{"key":"10_CR44","doi-asserted-by":"publisher","DOI":"10.1136\/openhrt-2017-000598","volume":"4","author":"Y Sato","year":"2017","unstructured":"Sato, Y. et al. Liver stiffness assessed by Fibrosis-4 index predicts mortality in patients with heart failure. Open Heart 4, e000598 (2017).","journal-title":"Open Heart"},{"key":"10_CR45","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1056\/NEJMra1313875","volume":"371","author":"CM Otto","year":"2014","unstructured":"Otto, C. M. & Prendergast, B. Aortic-valve stenosis \u2014 from patients at risk to severe valve obstruction. N. Engl. J. Med. 371, 744\u2013756 (2014).","journal-title":"N. Engl. J. Med."},{"key":"10_CR46","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1016\/j.atherosclerosis.2009.10.030","volume":"209","author":"H Volzke","year":"2010","unstructured":"Volzke, H. et al. Heart valve sclerosis predicts all-cause and cardiovascular mortality. Atherosclerosis 209, 606\u2013610 (2010).","journal-title":"Atherosclerosis"},{"key":"10_CR47","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.2337\/dc12-0134","volume":"35","author":"A Rossi","year":"2012","unstructured":"Rossi, A. et al. Aortic and mitral annular calcifications are predictive of all-cause and cardiovascular mortality in patients with type 2 diabetes. Diabetes Care 35, 1781\u20131786 (2012).","journal-title":"Diabetes Care"},{"key":"10_CR48","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1093\/europace\/euu265","volume":"17","author":"WT O\u2019Neal","year":"2015","unstructured":"O\u2019Neal, W. T. et al. Mitral annular calcification and incident atrial fibrillation in the Multi-Ethnic Study of Atherosclerosis. Europace 17, 358\u2013363 (2015).","journal-title":"Europace"},{"key":"10_CR49","doi-asserted-by":"publisher","first-page":"1690","DOI":"10.1161\/ATVBAHA.112.300556","volume":"33","author":"MR Markus","year":"2013","unstructured":"Markus, M. R. et al. Hepatic steatosis is associated with aortic valve sclerosis in the general population: the Study of Health in Pomerania (SHIP). Arterioscler. Thromb. Vasc. Biol. 33, 1690\u20131695 (2013).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10_CR50","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0088371","volume":"9","author":"S Bonapace","year":"2014","unstructured":"Bonapace, S. et al. Nonalcoholic fatty liver disease is associated with aortic valve sclerosis in patients with type 2 diabetes mellitus. PLoS ONE 9, e88371 (2014).","journal-title":"PLoS ONE"},{"key":"10_CR51","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1016\/j.metabol.2015.04.003","volume":"64","author":"A Mantovani","year":"2015","unstructured":"Mantovani, A. et al. Heart valve calcification in patients with type 2 diabetes and nonalcoholic fatty liver disease. Metabolism 64, 879\u2013887 (2015).","journal-title":"Metabolism"},{"key":"10_CR52","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1136\/gut.2007.139303","volume":"57","author":"JL Newton","year":"2008","unstructured":"Newton, J. L. et al. Fatigue in non-alcoholic fatty liver disease (NAFLD) is significant and associates with inactivity and excessive daytime sleepiness but not with liver disease severity or insulin resistance. Gut 57, 807\u2013813 (2008).","journal-title":"Gut"},{"key":"10_CR53","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0061803","volume":"8","author":"YC Liu","year":"2013","unstructured":"Liu, Y. C. et al. Influence of non-alcoholic fatty liver disease on autonomic changes evaluated by the time domain, frequency domain, and symbolic dynamics of heart rate variability. PLoS ONE 8, e61803 (2013).","journal-title":"PLoS ONE"},{"key":"10_CR54","doi-asserted-by":"publisher","first-page":"5160754","DOI":"10.1155\/2016\/5160754","volume":"2016","author":"MS Kumar","year":"2016","unstructured":"Kumar, M. S. et al. Cardiovascular autonomic dysfunction in patients of nonalcoholic fatty liver disease. Int. J. Hepatol. 2016, 5160754 (2016).","journal-title":"Int. J. Hepatol."},{"key":"10_CR55","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.12659\/MSM.890741","volume":"20","author":"O Ozveren","year":"2014","unstructured":"Ozveren, O. et al. Deterioration of heart rate recovery index in patients with non-alcoholic fatty liver disease (NAFLD). Med. Sci. Monit. 20, 1539\u20131543 (2014).","journal-title":"Med. Sci. Monit."},{"key":"10_CR56","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1089\/met.2016.0132","volume":"15","author":"KI Cho","year":"2017","unstructured":"Cho, K. I., Jo, E. A., Cho, S. H. & Kim, B. H. The influence of epicardial fat and nonalcoholic fatty liver disease on heart rate recovery in metabolic syndrome. Metab. Syndr. Relat. Disord. 15, 226\u2013232 (2017).","journal-title":"Metab. Syndr. Relat. Disord."},{"key":"10_CR57","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1042\/CS20130036","volume":"125","author":"G Targher","year":"2013","unstructured":"Targher, G. et al. Non-alcoholic fatty liver disease is associated with an increased prevalence of atrial fibrillation in hospitalized patients with type 2 diabetes. Clin. Sci. 125, 301\u2013309 (2013).","journal-title":"Clin. Sci."},{"key":"10_CR58","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0057183","volume":"8","author":"G Targher","year":"2013","unstructured":"Targher, G. et al. Non-alcoholic fatty liver disease is associated with an increased incidence of atrial fibrillation in patients with type 2 diabetes. PLoS ONE 8, e57183 (2013).","journal-title":"PLoS ONE"},{"key":"10_CR59","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.amjcard.2012.09.021","volume":"111","author":"MF Sinner","year":"2013","unstructured":"Sinner, M. F. et al. Relation of circulating liver transaminase concentrations to risk of new-onset atrial fibrillation. Am. J. Cardiol. 111, 219\u2013224 (2013).","journal-title":"Am. J. Cardiol."},{"key":"10_CR60","doi-asserted-by":"publisher","first-page":"4056","DOI":"10.1016\/j.ijcard.2013.07.035","volume":"168","author":"S Iscen","year":"2013","unstructured":"Iscen, S. RBBB is associated with an increased risk of NAFLD in young healthy individuals. Int. J. Cardiol. 168, 4056\u20134057 (2013).","journal-title":"Int. J. Cardiol."},{"key":"10_CR61","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1136\/heartjnl-2014-305756","volume":"100","author":"A Alonso","year":"2014","unstructured":"Alonso, A. et al. Circulating levels of liver enzymes and incidence of atrial fibrillation: the Atherosclerosis Risk in Communities cohort. Heart 100, 1511\u20131516 (2014).","journal-title":"Heart"},{"key":"10_CR62","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1016\/j.numecd.2014.01.005","volume":"24","author":"G Targher","year":"2014","unstructured":"Targher, G. et al. Association of nonalcoholic fatty liver disease with QTc interval in patients with type 2 diabetes. Nutr. Metab. Cardiovasc. Dis. 24, 663\u2013669 (2014).","journal-title":"Nutr. Metab. Cardiovasc. Dis."},{"key":"10_CR63","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0142937","volume":"10","author":"AJ Karajamaki","year":"2015","unstructured":"Karajamaki, A. J. et al. Non-alcoholic fatty liver disease as a predictor of atrial fibrillation in middle-aged population (OPERA Study). PLoS ONE 10, e0142937 (2015).","journal-title":"PLoS ONE"},{"key":"10_CR64","volume":"4","author":"CS Hung","year":"2015","unstructured":"Hung, C. S. et al. Nonalcoholic fatty liver disease is associated with QT prolongation in the general population. J. Am. Heart Assoc. 4, e001820 (2015).","journal-title":"J. Am. Heart Assoc."},{"key":"10_CR65","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.atherosclerosis.2015.12.023","volume":"245","author":"MR Markus","year":"2016","unstructured":"Markus, M. R. et al. Association between hepatic steatosis and serum liver enzyme levels with atrial fibrillation in the general population: the Study of Health in Pomerania (SHIP). Atherosclerosis 245, 123\u2013131 (2016).","journal-title":"Atherosclerosis"},{"key":"10_CR66","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.2337\/dc16-0091","volume":"39","author":"A Mantovani","year":"2016","unstructured":"Mantovani, A. et al. Nonalcoholic fatty liver disease is associated with ventricular arrhythmias in patients with type 2 diabetes referred for clinically indicated 24-hour holter monitoring. Diabetes Care 39, 1416\u20131423 (2016).","journal-title":"Diabetes Care"},{"key":"10_CR67","volume":"9","author":"MA Mangi","year":"2017","unstructured":"Mangi, M. A. et al. Association of non-alcoholic fatty liver disease with conduction defects on electrocardiogram. Cureus 9, e1107 (2017).","journal-title":"Cureus"},{"key":"10_CR68","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0173855","volume":"12","author":"AJ Karajamaki","year":"2017","unstructured":"Karajamaki, A. J. et al. Presence of atrial fibrillation is associated with liver stiffness in an elderly Finnish population. PLoS ONE 12, e0173855 (2017).","journal-title":"PLoS ONE"},{"key":"10_CR69","volume":"6","author":"MT Long","year":"2017","unstructured":"Long, M. T. et al. Relations of liver fat with prevalent and incident atrial fibrillation in the Framingham Heart Study. J. Am. Heart Assoc. 6, e005227 (2017).","journal-title":"J. Am. Heart Assoc."},{"key":"10_CR70","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0185459","volume":"12","author":"A Mantovani","year":"2017","unstructured":"Mantovani, A. et al. Nonalcoholic fatty liver disease is associated with an increased risk of heart block in hospitalized patients with type 2 diabetes mellitus. PLoS ONE 12, e0185459 (2017).","journal-title":"PLoS ONE"},{"key":"10_CR71","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1016\/S0140-6736(11)61514-6","volume":"379","author":"GY Lip","year":"2012","unstructured":"Lip, G. Y., Tse, H. F. & Lane, D. A. Atrial fibrillation. Lancet 379, 648\u2013661 (2012).","journal-title":"Lancet"},{"key":"10_CR72","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/j.clinre.2017.08.001","volume":"41","author":"K Wijarnpreecha","year":"2017","unstructured":"Wijarnpreecha, K., Boonpheng, B., Thongprayoon, C., Jaruvongvanich, V. & Ungprasert, P. The association between non-alcoholic fatty liver disease and atrial fibrillation: a meta-analysis. Clin. Res. Hepatol. Gastroenterol. 41, 525\u2013532 (2017).","journal-title":"Clin. Res. Hepatol. Gastroenterol"},{"key":"10_CR73","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/j.jacc.2005.08.067","volume":"47","author":"SM Straus","year":"2006","unstructured":"Straus, S. M. et al. Prolonged QTc interval and risk of sudden cardiac death in a population of older adults. J. Am. Coll. Cardiol. 47, 362\u2013367 (2006).","journal-title":"J. Am. Coll. Cardiol."},{"key":"10_CR74","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1136\/heartjnl-2012-302770","volume":"99","author":"AG Coumbe","year":"2013","unstructured":"Coumbe, A. G. et al. Long-term follow-up of older patients with Mobitz type I second degree atrioventricular block. Heart 99, 334\u2013338 (2013).","journal-title":"Heart"},{"key":"10_CR75","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1136\/heartjnl-2015-308956","volume":"102","author":"CS Kwok","year":"2016","unstructured":"Kwok, C. S. et al. Prolonged PR interval, first-degree heart block and adverse cardiovascular outcomes: a systematic review and meta-analysis. Heart 102, 672\u2013680 (2016).","journal-title":"Heart"},{"key":"10_CR76","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1146\/annurev-immunol-031210-101322","volume":"29","author":"MF Gregor","year":"2011","unstructured":"Gregor, M. F. & Hotamisligil, G. S. Inflammatory mechanisms in obesity. Annu. Rev. Immunol. 29, 415\u2013445 (2011).","journal-title":"Annu. Rev. Immunol."},{"key":"10_CR77","doi-asserted-by":"publisher","first-page":"1836","DOI":"10.1002\/hep.24001","volume":"52","author":"H Tilg","year":"2010","unstructured":"Tilg, H. & Moschen, A. R. Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis. Hepatology 52, 1836\u20131846 (2010).","journal-title":"Hepatology"},{"key":"10_CR78","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms5309","volume":"5","author":"YL Liu","year":"2014","unstructured":"Liu, Y. L. et al. TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease. Nat. Commun. 5, 4309 (2014).","journal-title":"Nat. Commun."},{"key":"10_CR79","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1055\/s-0035-1562947","volume":"35","author":"QM Anstee","year":"2015","unstructured":"Anstee, Q. M. & Day, C. P. The genetics of nonalcoholic fatty liver disease: spotlight on PNPLA3 and TM6SF2. Semin. Liver Dis. 35, 270\u2013290 (2015).","journal-title":"Semin. Liver Dis."},{"key":"10_CR80","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1053\/j.gastro.2015.01.038","volume":"148","author":"B Kahali","year":"2015","unstructured":"Kahali, B. et al. TM6SF2: catch-22 in the fight against nonalcoholic fatty liver disease and cardiovascular disease? Gastroenterology 148, 679\u2013684 (2015).","journal-title":"Gastroenterology"},{"key":"10_CR81","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.1053\/j.gastro.2016.01.037","volume":"150","author":"QM Anstee","year":"2016","unstructured":"Anstee, Q. M., Seth, D. & Day, C. P. Genetic factors that affect risk of alcoholic and nonalcoholic fatty liver disease. Gastroenterology 150, 1728\u20131744.e7 (2016).","journal-title":"Gastroenterology"},{"key":"10_CR82","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1002\/hep.28456","volume":"64","author":"H Tilg","year":"2016","unstructured":"Tilg, H., Moschen, A. R. & Szabo, G. Interleukin-1 and inflammasomes in alcoholic liver disease\/acute alcoholic hepatitis and nonalcoholic fatty liver disease\/nonalcoholic steatohepatitis. Hepatology 64, 955\u2013965 (2016).","journal-title":"Hepatology"},{"key":"10_CR83","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1038\/nm1166","volume":"11","author":"D Cai","year":"2005","unstructured":"Cai, D. et al. Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB. Nat. Med. 11, 183\u2013190 (2005).","journal-title":"Nat. Med"},{"key":"10_CR84","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1038\/nm1185","volume":"11","author":"MC Arkan","year":"2005","unstructured":"Arkan, M. C. et al. IKK-beta links inflammation to obesity-induced insulin resistance. Nat. Med. 11, 191\u2013198 (2005).","journal-title":"Nat. Med."},{"key":"10_CR85","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1038\/nm.3084","volume":"19","author":"S Kiechl","year":"2013","unstructured":"Kiechl, S. et al. Blockade of receptor activator of nuclear factor-kappaB (RANKL) signaling improves hepatic insulin resistance and prevents development of diabetes mellitus. Nat. Med. 19, 358\u2013363 (2013).","journal-title":"Nat. Med."},{"key":"10_CR86","first-page":"4196","volume":"82","author":"V Mohamed-Ali","year":"1997","unstructured":"Mohamed-Ali, V. et al. Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-alpha, in vivo. J. Clin. Endocrinol. Metab. 82, 4196\u20134200 (1997).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10_CR87","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1136\/gut.2010.214577","volume":"59","author":"AR Moschen","year":"2010","unstructured":"Moschen, A. R. et al. Anti-inflammatory effects of excessive weight loss: potent suppression of adipose interleukin 6 and tumour necrosis factor alpha expression. Gut 59, 1259\u20131264 (2010).","journal-title":"Gut"},{"key":"10_CR88","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1161\/ATVBAHA.114.303034","volume":"34","author":"CD Byrne","year":"2014","unstructured":"Byrne, C. D. & Targher, G. Ectopic fat, insulin resistance, and nonalcoholic fatty liver disease: implications for cardiovascular disease. Arterioscler. Thromb. Vasc. Biol. 34, 1155\u20131161 (2014).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10_CR89","doi-asserted-by":"publisher","first-page":"432","DOI":"10.2174\/1570161114666160722112738","volume":"14","author":"N Katsiki","year":"2016","unstructured":"Katsiki, N., Athyros, V. G. & Mikhailidis, D. P. Abnormal peri-organ or intra-organ fat (APIFat) deposition: an underestimated predictor of vascular risk? Curr. Vasc. Pharmacol. 14, 432\u2013441 (2016).","journal-title":"Curr. Vasc. Pharmacol."},{"key":"10_CR90","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1038\/nature10213","volume":"474","author":"AL Kau","year":"2011","unstructured":"Kau, A. L., Ahern, P. P., Griffin, N. W., Goodman, A. L. & Gordon, J. I. Human nutrition, the gut microbiome and the immune system. Nature 474, 327\u2013336 (2011).","journal-title":"Nature"},{"key":"10_CR91","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1053\/j.gastro.2014.12.036","volume":"148","author":"H Tilg","year":"2015","unstructured":"Tilg, H. & Moschen, A. R. Food, immunity, and the microbiome. Gastroenterology 148, 1107\u20131119 (2015).","journal-title":"Gastroenterology"},{"issue":"Suppl. 1","key":"10_CR92","doi-asserted-by":"publisher","first-page":"S50","DOI":"10.1016\/j.ejphar.2011.05.085","volume":"668","author":"PC Calder","year":"2011","unstructured":"Calder, P. C. Fatty acids and inflammation: the cutting edge between food and pharma. Eur. J. Pharmacol. 668 (Suppl. 1), S50\u2013S58 (2011).","journal-title":"Eur. J. Pharmacol."},{"key":"10_CR93","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1053\/j.gastro.2012.01.034","volume":"142","author":"S Pendyala","year":"2012","unstructured":"Pendyala, S., Walker, J. M. & Holt, P. R. A high-fat diet is associated with endotoxemia that originates from the gut. Gastroenterology 142, 1100\u20131101.e2 (2012).","journal-title":"Gastroenterology"},{"key":"10_CR94","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/nature09922","volume":"472","author":"Z Wang","year":"2011","unstructured":"Wang, Z. et al. Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature 472, 57\u201363 (2011).","journal-title":"Nature"},{"key":"10_CR95","doi-asserted-by":"publisher","DOI":"10.1038\/srep19076","volume":"6","author":"YM Chen","year":"2016","unstructured":"Chen, Y. M. et al. Associations of gut-flora-dependent metabolite trimethylamine-N-oxide, betaine and choline with non-alcoholic fatty liver disease in adults. Sci. Rep. 6, 19076 (2016).","journal-title":"Sci. Rep"},{"key":"10_CR96","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1016\/j.cmet.2017.04.001","volume":"25","author":"R Loomba","year":"2017","unstructured":"Loomba, R. et al. Gut microbiome-based metagenomic signature for non-invasive detection of advanced fibrosis in human nonalcoholic fatty liver disease. Cell Metab. 25, 1054\u20131062.e5 (2017).","journal-title":"Cell Metab."},{"key":"10_CR97","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/j.tem.2013.05.009","volume":"24","author":"AR Moschen","year":"2013","unstructured":"Moschen, A. R., Kaser, S. & Tilg, H. Non-alcoholic steatohepatitis: a microbiota-driven disease. Trends Endocrinol. Metab. 24, 537\u2013545 (2013).","journal-title":"Trends Endocrinol. Metab."},{"key":"10_CR98","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.1136\/gutjnl-2017-313872","volume":"66","author":"F Shanahan","year":"2017","unstructured":"Shanahan, F., van Sinderen, D., O\u2019Toole, P. W. & Stanton, C. Feeding the microbiota: transducer of nutrient signals for the host. Gut 66, 1709\u20131717 (2017).","journal-title":"Gut"},{"key":"10_CR99","doi-asserted-by":"publisher","first-page":"5902947","DOI":"10.1155\/2016\/5902947","volume":"2016","author":"V Dusi","year":"2016","unstructured":"Dusi, V., Ghidoni, A., Ravera, A., De Ferrari, G. M. & Calvillo, L. Chemokines and heart disease: a network connecting cardiovascular biology to immune and autonomic nervous systems. Mediators Inflamm. 2016, 5902947 (2016).","journal-title":"Mediators Inflamm."},{"key":"10_CR100","first-page":"1717","volume":"38","author":"PE Lazzerini","year":"2017","unstructured":"Lazzerini, P. E., Capecchi, P. L. & Laghi-Pasini, F. Systemic inflammation and arrhythmic risk: lessons from rheumatoid arthritis. Eur. Heart J. 38, 1717\u20131727 (2017).","journal-title":"Eur. Heart J."},{"key":"10_CR101","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1177\/0003319717709380","volume":"69","author":"T Yalta","year":"2017","unstructured":"Yalta, T. & Yalta, K. Systemic inflammation and arrhythmogenesis: a review of mechanistic and clinical perspectives. Angiology 69, 288\u2013296 (2017).","journal-title":"Angiology"},{"key":"10_CR102","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1038\/nature08938","volume":"464","author":"P Duewell","year":"2010","unstructured":"Duewell, P. et al. NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature 464, 1357\u20131361 (2010).","journal-title":"Nature"},{"key":"10_CR103","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","volume":"377","author":"PM Ridker","year":"2017","unstructured":"Ridker, P. M. et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N. Engl. J. Med. 377, 1119\u20131131 (2017).","journal-title":"N. Engl. J. Med."},{"key":"10_CR104","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms13344","volume":"7","author":"G Monnerat","year":"2016","unstructured":"Monnerat, G. et al. Macrophage-dependent IL-1beta production induces cardiac arrhythmias in diabetic mice. Nat. Commun. 7, 13344 (2016).","journal-title":"Nat. Commun."},{"key":"10_CR105","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms7018","volume":"6","author":"R Aschar-Sobbi","year":"2015","unstructured":"Aschar-Sobbi, R. et al. Increased atrial arrhythmia susceptibility induced by intense endurance exercise in mice requires TNFalpha. Nat. Commun. 6, 6018 (2015).","journal-title":"Nat. Commun."},{"key":"10_CR106","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1007\/s00424-013-1320-2","volume":"465","author":"DV Abramochkin","year":"2013","unstructured":"Abramochkin, D. V. et al. TNF-alpha provokes electrical abnormalities in rat atrial myocardium via a NO-dependent mechanism. Pflugers Arch. 465, 1741\u20131752 (2013).","journal-title":"Pflugers Arch."},{"key":"10_CR107","doi-asserted-by":"publisher","first-page":"H431","DOI":"10.1152\/ajpheart.00431.2002","volume":"284","author":"B London","year":"2003","unstructured":"London, B. et al. Calcium-dependent arrhythmias in transgenic mice with heart failure. Am. J. Physiol. Heart Circ. Physiol. 284, H431\u2013H441 (2003).","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"10_CR108","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1253\/circj.70.605","volume":"70","author":"H Kawada","year":"2006","unstructured":"Kawada, H. et al. Tumor necrosis factor-alpha downregulates the voltage gated outward K+ current in cultured neonatal rat cardiomyocytes: a possible cause of electrical remodeling in diseased hearts. Circ. J. 70, 605\u2013609 (2006).","journal-title":"Circ. J."},{"key":"10_CR109","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1161\/CIRCRESAHA.110.229112","volume":"108","author":"BK Panama","year":"2011","unstructured":"Panama, B. K. et al. Nuclear factor kappaB downregulates the transient outward potassium current I(to,f) through control of KChIP2 expression. Circ. Res. 108, 537\u2013543 (2011).","journal-title":"Circ. Res."},{"key":"10_CR110","doi-asserted-by":"publisher","first-page":"83","DOI":"10.3892\/ijmm.2015.2204","volume":"36","author":"XX Fu","year":"2015","unstructured":"Fu, X. X. et al. Interleukin-17A contributes to the development of post-operative atrial fibrillation by regulating inflammation and fibrosis in rats with sterile pericarditis. Int. J. Mol. Med. 36, 83\u201392 (2015).","journal-title":"Int. J. Mol. Med"},{"key":"10_CR111","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.yjmcc.2015.11.034","volume":"90","author":"K Takahashi","year":"2016","unstructured":"Takahashi, K. et al. High-fat diet increases vulnerability to atrial arrhythmia by conduction disturbance via miR-27b. J. Mol. Cell Cardiol. 90, 38\u201346 (2016).","journal-title":"J. Mol. Cell Cardiol."},{"key":"10_CR112","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0104771","volume":"9","author":"B Luo","year":"2014","unstructured":"Luo, B. et al. NLRP3 gene silencing ameliorates diabetic cardiomyopathy in a type 2 diabetes rat model. PLoS ONE 9, e104771 (2014).","journal-title":"PLoS ONE"},{"key":"10_CR113","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/FJC.0000000000000106","volume":"64","author":"S Toldo","year":"2014","unstructured":"Toldo, S. et al. Interleukin-1beta blockade improves left ventricular systolic\/diastolic function and restores contractility reserve in severe ischemic cardiomyopathy in the mouse. J. Cardiovasc. Pharmacol. 64, 1\u20136 (2014).","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"10_CR114","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s11897-014-0231-7","volume":"12","author":"BW Tassell Van","year":"2015","unstructured":"Van Tassell, B. W., Raleigh, J. M. & Abbate, A. Targeting interleukin-1 in heart failure and inflammatory heart disease. Curr. Heart Fail. Rep. 12, 33\u201341 (2015).","journal-title":"Curr. Heart Fail. Rep"},{"key":"10_CR115","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0148189","volume":"11","author":"RL Amdur","year":"2016","unstructured":"Amdur, R. L. et al. Interleukin-6 is a risk factor for atrial fibrillation in chronic kidney disease: findings from the CRIC study. PLoS ONE 11, e0148189 (2016).","journal-title":"PLoS ONE"},{"key":"10_CR116","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.ijcard.2013.08.078","volume":"169","author":"N Wu","year":"2013","unstructured":"Wu, N. et al. Association of inflammatory factors with occurrence and recurrence of atrial fibrillation: a meta-analysis. Int. J. Cardiol. 169, 62\u201372 (2013).","journal-title":"Int. J. Cardiol."},{"key":"10_CR117","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1002\/hep.29367","volume":"67","author":"N Chalasani","year":"2017","unstructured":"Chalasani, N. et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology 67, 328\u2013357 (2017).","journal-title":"Hepatology"},{"key":"10_CR118","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1001\/jamainternmed.2016.3202","volume":"176","author":"HJ Zhang","year":"2016","unstructured":"Zhang, H. J. et al. Effects of moderate and vigorous exercise on nonalcoholic fatty liver disease: a randomized clinical trial. JAMA Intern. Med. 176, 1074\u20131082 (2016).","journal-title":"JAMA Intern. Med."},{"key":"10_CR119","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1002\/hep.23276","volume":"51","author":"K Promrat","year":"2010","unstructured":"Promrat, K. et al. Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepatology 51, 121\u2013129 (2010).","journal-title":"Hepatology"},{"key":"10_CR120","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1053\/j.gastro.2015.04.005","volume":"149","author":"E Vilar-Gomez","year":"2015","unstructured":"Vilar-Gomez, E. et al. Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis. Gastroenterology 149, 367\u2013378 (2015).","journal-title":"Gastroenterology"},{"key":"10_CR121","doi-asserted-by":"publisher","first-page":"6659","DOI":"10.1073\/pnas.0308291101","volume":"101","author":"L Fontana","year":"2004","unstructured":"Fontana, L., Meyer, T. E., Klein, S. & Holloszy, J. O. Long-term calorie restriction is highly effective in reducing the risk for atherosclerosis in humans. Proc. Natl Acad. Sci. USA 101, 6659\u20136663 (2004).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"10_CR122","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.cjca.2014.08.004","volume":"31","author":"PP Gupta","year":"2015","unstructured":"Gupta, P. P., Fonarow, G. C. & Horwich, T. B. Obesity and the obesity paradox in heart failure. Can. J. Cardiol. 31, 195\u2013202 (2015).","journal-title":"Can. J. Cardiol."},{"key":"10_CR123","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1007\/s10620-016-4040-6","volume":"61","author":"A Mantovani","year":"2016","unstructured":"Mantovani, A., Ballestri, S., Lonardo, A. & Targher, G. Cardiovascular disease and myocardial abnormalities in nonalcoholic fatty liver disease. Dig. Dis. Sci. 61, 1246\u20131267 (2016).","journal-title":"Dig. Dis. Sci."},{"key":"10_CR124","doi-asserted-by":"publisher","first-page":"19","DOI":"10.2147\/DMSO.S124541","volume":"10","author":"S Karimian","year":"2017","unstructured":"Karimian, S., Stein, J., Bauer, B. & Teupe, C. Improvement of impaired diastolic left ventricular function after diet-induced weight reduction in severe obesity. Diabetes Metab. Syndr. Obes. 10, 19\u201325 (2017).","journal-title":"Diabetes Metab. Syndr. Obes."},{"key":"10_CR125","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.tcm.2014.09.005","volume":"25","author":"R Mahajan","year":"2015","unstructured":"Mahajan, R., Lau, D. H. & Sanders, P. Impact of obesity on cardiac metabolism, fibrosis, and function. Trends Cardiovasc. Med. 25, 119\u2013126 (2015).","journal-title":"Trends Cardiovasc. Med."},{"key":"10_CR126","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1016\/j.amjcard.2011.06.076","volume":"108","author":"HM Heneghan","year":"2011","unstructured":"Heneghan, H. M., Meron-Eldar, S., Brethauer, S. A., Schauer, P. R. & Young, J. B. Effect of bariatric surgery on cardiovascular risk profile. Am. J. Cardiol. 108, 1499\u20131507 (2011).","journal-title":"Am. J. Cardiol."},{"key":"10_CR127","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1161\/CIR.0b013e3182149099","volume":"123","author":"P Poirier","year":"2011","unstructured":"Poirier, P. et al. Bariatric surgery and cardiovascular risk factors: a scientific statement from the American Heart Association. Circulation 123, 1683\u20131701 (2011).","journal-title":"Circulation"},{"key":"10_CR128","doi-asserted-by":"publisher","first-page":"2376","DOI":"10.1016\/j.jacc.2009.07.054","volume":"54","author":"L las Fuentes de","year":"2009","unstructured":"de las Fuentes, L. et al. Effect of moderate diet-induced weight loss and weight regain on cardiovascular structure and function. J. Am. Coll. Cardiol. 54, 2376\u20132381 (2009).","journal-title":"J. Am. Coll. Cardiol."},{"key":"10_CR129","doi-asserted-by":"publisher","first-page":"568","DOI":"10.7326\/M14-0130","volume":"161","author":"JS Lin","year":"2014","unstructured":"Lin, J. S. et al. Behavioral counseling to promote a healthy lifestyle in persons with cardiovascular risk factors: a systematic review for the U.S. Preventive Services Task Force. Ann. Intern. Med. 161, 568\u2013578 (2014).","journal-title":"Ann. Intern. Med."},{"key":"10_CR130","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1042\/CS20150308","volume":"129","author":"K Hallsworth","year":"2015","unstructured":"Hallsworth, K. et al. Modified high-intensity interval training reduces liver fat and improves cardiac function in non-alcoholic fatty liver disease: a randomized controlled trial. Clin. Sci. 129, 1097\u20131105 (2015).","journal-title":"Clin. Sci."},{"key":"10_CR131","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1016\/S0735-1097(01)01448-6","volume":"38","author":"TB Horwich","year":"2001","unstructured":"Horwich, T. B. et al. The relationship between obesity and mortality in patients with heart failure. J. Am. Coll. Cardiol. 38, 789\u2013795 (2001).","journal-title":"J. Am. Coll. Cardiol."},{"key":"10_CR132","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1016\/j.ahj.2005.02.004","volume":"150","author":"B Bozkurt","year":"2005","unstructured":"Bozkurt, B. & Deswal, A. Obesity as a prognostic factor in chronic symptomatic heart failure. Am. Heart J. 150, 1233\u20131239 (2005).","journal-title":"Am. Heart J."},{"key":"10_CR133","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.ahj.2008.02.014","volume":"156","author":"A Oreopoulos","year":"2008","unstructured":"Oreopoulos, A. et al. Body mass index and mortality in heart failure: a meta-analysis. Am. Heart J. 156, 13\u201322 (2008).","journal-title":"Am. Heart J."},{"key":"10_CR134","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.jhep.2009.10.010","volume":"52","author":"J Frith","year":"2010","unstructured":"Frith, J. et al. Potential strategies to improve uptake of exercise interventions in non-alcoholic fatty liver disease. J. Hepatol. 52, 112\u2013116 (2010).","journal-title":"J. Hepatol."},{"key":"10_CR135","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1016\/j.jhep.2012.11.031","volume":"58","author":"E Centis","year":"2013","unstructured":"Centis, E. et al. Stage of change and motivation to healthier lifestyle in non-alcoholic fatty liver disease. J. Hepatol. 58, 771\u2013777 (2013).","journal-title":"J. Hepatol."},{"key":"10_CR136","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1053\/j.gastro.2015.04.043","volume":"149","author":"P Angulo","year":"2015","unstructured":"Angulo, P. et al. Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology 149, 389\u2013397.e10 (2015).","journal-title":"Gastroenterology"},{"key":"10_CR137","first-page":"CD004816","volume":"1","author":"F Taylor","year":"2013","unstructured":"Taylor, F. et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst. Rev. 1, CD004816 (2013).","journal-title":"Cochrane Database Syst. Rev."},{"key":"10_CR138","doi-asserted-by":"publisher","first-page":"g4379","DOI":"10.1136\/bmj.g4379","volume":"349","author":"D Keene","year":"2014","unstructured":"Keene, D., Price, C., Shun-Shin, M. J. & Francis, D. P. Effect on cardiovascular risk of high density lipoprotein targeted drug treatments niacin, fibrates, and CETP inhibitors: meta-analysis of randomised controlled trials including 117,411 patients. BMJ 349, g4379 (2014).","journal-title":"BMJ"},{"key":"10_CR139","doi-asserted-by":"publisher","first-page":"468","DOI":"10.7326\/M13-2526","volume":"160","author":"KA Gudzune","year":"2014","unstructured":"Gudzune, K. A. et al. Effectiveness of combination therapy with statin and another lipid-modifying agent compared with intensified statin monotherapy: a systematic review. Ann. Intern. Med. 160, 468\u2013476 (2014).","journal-title":"Ann. Intern. Med."},{"key":"10_CR140","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1016\/j.jhep.2015.05.006","volume":"63","author":"P Dongiovanni","year":"2015","unstructured":"Dongiovanni, P. et al. Statin use and non-alcoholic steatohepatitis in at risk individuals. J. Hepatol. 63, 705\u2013712 (2015).","journal-title":"J. Hepatol."},{"key":"10_CR141","doi-asserted-by":"publisher","first-page":"1654","DOI":"10.1111\/j.1440-1746.2012.07232.x","volume":"27","author":"A Lonardo","year":"2012","unstructured":"Lonardo, A. & Loria, P. Potential for statins in the chemoprevention and management of hepatocellular carcinoma. J. Gastroenterol. Hepatol. 27, 1654\u20131664 (2012).","journal-title":"J. Gastroenterol. Hepatol."},{"key":"10_CR142","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1097\/MAJ.0b013e3181e15da8","volume":"340","author":"FS Rzouq","year":"2010","unstructured":"Rzouq, F. S. et al. Hepatotoxicity fears contribute to underutilization of statin medications by primary care physicians. Am. J. Med. Sci. 340, 89\u201393 (2010).","journal-title":"Am. J. Med. Sci."},{"key":"10_CR143","doi-asserted-by":"publisher","first-page":"S47","DOI":"10.1016\/j.jacl.2014.02.011","volume":"8","author":"H Bays","year":"2014","unstructured":"Bays, H., Cohen, D. E., Chalasani, N., Harrison, S. A. & The National Lipid Association\u2019s Statin Safety Task Force. An assessment by the statin liver safety task force: 2014 update. J. Clin. Lipidol. 8, S47\u2013S57 (2014).","journal-title":"J. Clin. Lipidol."},{"key":"10_CR144","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1007\/s10620-012-2207-3","volume":"57","author":"JH Lewis","year":"2012","unstructured":"Lewis, J. H. Clinical perspective: statins and the liver \u2014 harmful or helpful? Dig. Dis. Sci. 57, 1754\u20131763 (2012).","journal-title":"Dig. Dis. Sci."},{"key":"10_CR145","doi-asserted-by":"publisher","first-page":"1916","DOI":"10.1016\/S0140-6736(10)61272-X","volume":"376","author":"VG Athyros","year":"2010","unstructured":"Athyros, V. G. et al. Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis. Lancet 376, 1916\u20131922 (2010).","journal-title":"Lancet"},{"key":"10_CR146","doi-asserted-by":"publisher","first-page":"3846","DOI":"10.1016\/j.ijcard.2013.06.024","volume":"168","author":"MJ Tikkanen","year":"2013","unstructured":"Tikkanen, M. J. et al. Effect of intensive lipid lowering with atorvastatin on cardiovascular outcomes in coronary heart disease patients with mild-to-moderate baseline elevations in alanine aminotransferase levels. Int. J. Cardiol. 168, 3846\u20133852 (2013).","journal-title":"Int. J. Cardiol."},{"key":"10_CR147","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1002\/hep.23623","volume":"52","author":"G Musso","year":"2010","unstructured":"Musso, G., Gambino, R., Cassader, M. & Pagano, G. A meta-analysis of randomized trials for the treatment of nonalcoholic fatty liver disease. Hepatology 52, 79\u2013104 (2010).","journal-title":"Hepatology"},{"key":"10_CR148","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1002\/hep.21638","volume":"45","author":"A Hirose","year":"2007","unstructured":"Hirose, A. et al. Angiotensin II type 1 receptor blocker inhibits fibrosis in rat nonalcoholic steatohepatitis. Hepatology 45, 1375\u20131381 (2007).","journal-title":"Hepatology"},{"key":"10_CR149","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1002\/hep.20420","volume":"40","author":"S Yokohama","year":"2004","unstructured":"Yokohama, S. et al. Therapeutic efficacy of an angiotensin II receptor antagonist in patients with nonalcoholic steatohepatitis. Hepatology 40, 1222\u20131225 (2004).","journal-title":"Hepatology"},{"key":"10_CR150","doi-asserted-by":"publisher","first-page":"942","DOI":"10.3748\/wjg.15.942","volume":"15","author":"EF Georgescu","year":"2009","unstructured":"Georgescu, E. F., Ionescu, R., Niculescu, M., Mogoanta, L. & Vancica, L. Angiotensin-receptor blockers as therapy for mild-to-moderate hypertension-associated non-alcoholic steatohepatitis. World J. Gastroenterol. 15, 942\u2013954 (2009).","journal-title":"World J. Gastroenterol."},{"key":"10_CR151","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0175717","volume":"12","author":"S McPherson","year":"2017","unstructured":"McPherson, S. et al. A randomised controlled trial of losartan as an anti-fibrotic agent in non-alcoholic steatohepatitis. PLoS ONE 12, e0175717 (2017).","journal-title":"PLoS ONE"},{"key":"10_CR152","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1053\/j.gastro.2014.04.046","volume":"147","author":"AJ Sanyal","year":"2014","unstructured":"Sanyal, A. J. et al. No significant effects of ethyl-eicosapentanoic acid on histologic features of nonalcoholic steatohepatitis in a phase 2 trial. Gastroenterology 147, 377\u2013384.e1 (2014).","journal-title":"Gastroenterology"},{"key":"10_CR153","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.jhep.2014.08.036","volume":"62","author":"CK Argo","year":"2015","unstructured":"Argo, C. K. et al. Effects of n-3 fish oil on metabolic and histological parameters in NASH: a double-blind, randomized, placebo-controlled trial. J. Hepatol. 62, 190\u2013197 (2015).","journal-title":"J. Hepatol."},{"key":"10_CR154","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1016\/j.cmet.2014.09.018","volume":"20","author":"M Foretz","year":"2014","unstructured":"Foretz, M., Guigas, B., Bertrand, L., Pollak, M. & Viollet, B. Metformin: from mechanisms of action to therapies. Cell Metab. 20, 953\u2013966 (2014).","journal-title":"Cell Metab."},{"key":"10_CR155","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1136\/gutjnl-2011-301708","volume":"62","author":"HP Chen","year":"2013","unstructured":"Chen, H. P. et al. Metformin decreases hepatocellular carcinoma risk in a dose-dependent manner: population-based and in vitro studies. Gut 62, 606\u2013615 (2013).","journal-title":"Gut"},{"key":"10_CR156","doi-asserted-by":"publisher","first-page":"2347","DOI":"10.1210\/jc.2012-1267","volume":"97","author":"ZJ Zhang","year":"2012","unstructured":"Zhang, Z. J. et al. Metformin for liver cancer prevention in patients with type 2 diabetes: a systematic review and meta-analysis. J. Clin. Endocrinol. Metab. 97, 2347\u20132353 (2012).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10_CR157","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1056\/NEJMoa0907929","volume":"362","author":"AJ Sanyal","year":"2010","unstructured":"Sanyal, A. J. et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N. Engl. J. Med. 362, 1675\u20131685 (2010).","journal-title":"N. Engl. J. Med."},{"key":"10_CR158","doi-asserted-by":"publisher","first-page":"305","DOI":"10.7326\/M15-1774","volume":"165","author":"K Cusi","year":"2016","unstructured":"Cusi, K. et al. Long-term pioglitazone treatment for patients with nonalcoholic steatohepatitis and prediabetes or type 2 diabetes mellitus: a randomized trial. Ann. Intern. Med. 165, 305\u2013315 (2016).","journal-title":"Ann. Intern. Med."},{"key":"10_CR159","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1016\/S0140-6736(15)00803-X","volume":"387","author":"MJ Armstrong","year":"2016","unstructured":"Armstrong, M. J. et al. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet 387, 679\u2013690 (2016).","journal-title":"Lancet"},{"key":"10_CR160","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1603827","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso, S. P. et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N. Engl. J. Med. 375, 311\u2013322 (2016).","journal-title":"N. Engl. J. Med."},{"key":"10_CR161","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1111\/liv.13270","volume":"37","author":"H Perazzo","year":"2017","unstructured":"Perazzo, H. & Dufour, J. F. The therapeutic landscape of non-alcoholic steatohepatitis. Liver Int. 37, 634\u2013647 (2017).","journal-title":"Liver Int."},{"key":"10_CR162","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1016\/S0140-6736(14)61933-4","volume":"385","author":"BA Neuschwander-Tetri","year":"2015","unstructured":"Neuschwander-Tetri, B. A. et al. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet 385, 956\u2013965 (2015).","journal-title":"Lancet"},{"key":"10_CR163","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1053\/j.gastro.2016.01.038","volume":"150","author":"V Ratziu","year":"2016","unstructured":"Ratziu, V. et al. Elafibranor, an agonist of the peroxisome proliferator-activated receptor-alpha and -delta, induces resolution of nonalcoholic steatohepatitis without fibrosis worsening. Gastroenterology 150, 1147\u20131159.e5 (2016).","journal-title":"Gastroenterology"},{"key":"10_CR164","doi-asserted-by":"publisher","unstructured":"Friedman, S. L. et al. A randomized, placebo-ontrolled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis. Hepatology \n                    https:\/\/doi.org\/10.1002\/hep.29477\n                    \n                   (2018).","DOI":"10.1002\/hep.29477"},{"key":"10_CR165","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1002\/hep.29514","volume":"67","author":"R Loomba","year":"2018","unstructured":"Loomba, R. et al. The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis: a randomized, phase 2 trial. Hepatology 67, 549\u2013559 (2018).","journal-title":"Hepatology"}],"container-title":["Nature Reviews Gastroenterology & Hepatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41575-018-0010-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41575-018-0010-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41575-018-0010-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T17:50:08Z","timestamp":1684605008000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41575-018-0010-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4,30]]},"references-count":165,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2018,7]]}},"alternative-id":["10"],"URL":"https:\/\/doi.org\/10.1038\/s41575-018-0010-0","relation":{},"ISSN":["1759-5045","1759-5053"],"issn-type":[{"value":"1759-5045","type":"print"},{"value":"1759-5053","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,4,30]]},"assertion":[{"value":"30 April 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}